Sterol methyltransferase a target for anti-amoeba therapy: towards transition state analog and suicide substrate drug design

• Main Authors: Medhanie E. Kidane, Boden H. Vanderloop, Wenxu Zhou, Crista D. Thomas, Emilio Ramos, Ujjal Singha, Minu Chaudhuri, W. David Nes
• Format: Article
• Language: English
• Published: Elsevier 2017-12-01
• Series: Journal of Lipid Research
• Subjects: phytosterol biosynthesis; sterol C24-methyltransferase; ergosterol biosynthesis inhibitors; Acanthamoeba; anti-amoeba drugs
• Online Access: http://www.sciencedirect.com/science/article/pii/S0022227520335574

Ergosterol biosynthesis pathways essential to pathogenic protozoa growth and absent from the human host offer new chokepoint targets. Here, we present characterization and cell-based interference of Acanthamoeba spp sterol 24-/28-methylases (SMTs) that catalyze the committed step in C28- and C29-sterol synthesis. Intriguingly, our kinetic analyses suggest that 24-SMT prefers plant cycloartenol whereas 28-SMT prefers 24(28)-methylene lophenol in similar fashion to the substrate preferences of land plant SMT1 and SMT2. Transition state analog-24(R,S),25-epiminolanosterol (EL) and suicide substrate 26,27-dehydrolanosterol (DHL) differentially inhibited trophozoite growth with IC50 values of 7 nM and 6 µM, respectively, and EL yielded 20-fold higher activity than reference drug voriconazole. Against either SMT assayed with native substrate, EL exhibited tight binding ∼Ki 9 nM. Alternatively, DHL is methylated at C26 by 24-SMT that thereby, generates intermediates that complex and inactivate the enzyme, whereas DHL is not productively bound to 28-SMT. Steroidal inhibitors had no effect on human epithelial kidney cell growth or cholesterol biosynthesis at minimum amoebicidal concentrations. We hypothesize the selective inhibition of Acanthamoeba by steroidal inhibitors representing distinct chemotypes may be an efficient strategy for the development of promising compounds to combat amoeba diseases.